News - Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali MEd pharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
01 November 2023News - Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its 440m² analytical laboratory in Fordham, Cambridgeshire, UK.
30 June 2023News - Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.
17 May 2023News - The Analytical and Materials Science (AMS) team has experienced significant growth since its inception 11 years ago and have outgrown their current lab space. To meet this rising demand, we have started work on reimagining an empty area of our site into a new state-of-the-art AMS laboratory. This lab will be over 30% larger, providing over 440 square metres of dedicated space for analytical and materials science work.
20 February 2023